ICAAC 46th

Title Content type
In Vitro Activity of the New Azole BAL4815 and other Antifungal Agents against Candida Bloodstream Isolates (click for details)
In Vitro Activity of the New Azole Isavuconazole (BAL 4815) Compared with Six other Antifungal Agents against 155 Cryptococcus neoformans Isolates from Cuba (click for details)
Donor’s Toll-like Receptor (TLR) 4 Haplotypes Increase the Incidence of Invasive Mold Infections (IMI) in Hematopoietic Stem Cell Transplant (HCT) Recipients. (click for details)
Pharmacokinetics (PK) and Safety of Posaconazole (POS) as Prophylaxis for Invasive Fungal Infection (IFI) in High-Risk Patients (Pts). (click for details)
Global Surveillance of the In Vitro Activity of Micafungin against Candida: A Comparison with Caspofungin Using Clinical and Laboratory Standards Institute Recommended Methods. (click for details)
Development and Evaluation of an XTT Assay for Rapid Susceptibility Testing of Aspergillus Spp. (click for details)
Evaluation of Disk Diffusion (DD) and Etest Compared to Broth Microdilution (BMD) Antifungal Susceptibility Testing (AFST) of Posaconazole (POS) against Clinical Isolates of Filamentous Fungi. (click for details)
Evaluation of Amphotericin B (AB) Activity Against Candida Spp Biofilms (BF) Using Metabolic Indicators (MTT, XTT and Resazurin). (click for details)
Effects of Human Polymorphonuclear Neutrophils (PMNs) Alone or in Combination with Caspofungin (CAS) Against Candida Albicans Biofilms. (click for details)
Treatment of Invasive Aspergillosis (IA) in Pediatric Patients (Pts) with Micafungin (MICA) Alone or in Combination with Other Systemic Antifungal Agents. (click for details)


Subscribe to ICAAC 46th